

## Timely insights from portfolio managers and industry experts on key financial, economic and political issues.

*The views expressed in these posts are those of the authors and are current only through the date stated. These views are subject to change at any time based upon market or other conditions, and Eaton Vance disclaims any responsibility to update such views. These views may not be relied upon as investment advice and, because investment decisions for Eaton Vance are based on many factors, may not be relied upon as an indication of trading intent on behalf of any Eaton Vance strategy. The discussion herein is general in nature and is provided for informational purposes only. There is no guarantee as to its accuracy or completeness.*

MARCH 11, 2021

[Global Investing | Markets and Economy](#)

### Bullish and bearish COVID-19 developments: Pandemic reaches one-year anniversary

**Boston** - Headlines tracking the scope of the coronavirus pandemic can drive investor sentiment. We monitor key reports to gain visibility into when the global economy can truly reopen. Here are the latest developments that we consider either bullish or bearish, the health policy responses and the economic impacts related to COVID-19.

#### Bullish virus developments

- Lab testing shows that the Pfizer vaccine is effective against the Brazil variant, with a neutralizing ability equivalent to its effect on the less contagious version of the coronavirus.
- Moderna has begun human testing for its COVID-19 variant vaccine targeting the South Africa strain.
- The FDA authorized a new T-cell test that could be a "game changer" for COVID-19 long haulers. The test could bring clarity to many patients who have not yet received definitive proof that they were once infected with the virus.
- Through March 10, the U.S. has given 93.7 million vaccination doses, and 10% of the U.S. population has received both doses of the shots.

#### Bearish virus developments

- As of March 11 —365 days since the World Health Organization declared COVID-19 a pandemic — the global death toll has climbed above 2,630,000, including more than 540,000 in the U.S.
- An outbreak of COVID-19 in British Columbia was reported in a nursing home where residents and staff were already vaccinated. Two staff members and 10 residents tested positive in the 221-bed facility.
- A peer-reviewed study warns that Pfizer and Moderna vaccines could be far less effective against the South Africa variant. In a laboratory study of blood sera, Moderna's vaccine candidate was found to be 12.4 times less effective against the South African variant, and Pfizer's vaccine to be about 10.3 times less effective.

#### Health policy responses

- The U.S. Embassy is urging Americans to avoid traveling to Mexico for spring break due to high levels of COVID infections there.
- The U.K. "furiously" denounced claims by the European Council's president that it had imposed a vaccine export ban. The statement also came days after Italy, with the European Commission's consent, blocked the shipment of vaccine doses to Australia.
- Prime Minister Boris Johnson welcomed the reopening of schools in the U.K. on March 8, calling it a "cautious, but irreversible" return to normality.
- Greece will welcome vaccinated and COVID-negative tourists starting in May.

Picture  
of

**Marshall L. Stocker,  
Ph.D., CFA**  
Director of Country  
Research and Portfolio  
Manager  
Eaton Vance  
Management

"As of March 11 —365 days since the World Health Organization declared COVID-19 a pandemic — the global death toll has climbed above 2,630,000, including more than 540,000 in the U.S."

- New Zealand says it has purchased enough doses of the Pfizer vaccine to inoculate its entire population of nearly five million.
- The CDC loosened rules, saying vaccinated individuals can visit indoors without masks, but must still wear them in public and avoid large gatherings when around those who are not immunized. The CDC also continued to urge people to delay all travel.
- Alaska made vaccines available to those 16 and older, becoming the first state to remove eligibility requirements. On March 10, New Yorkers older than 60 became eligible for the vaccine.
- Citigroup has begun providing certain branch workers and traders with at-home rapid COVID-19 tests as part of a larger study with a researcher at Harvard University. Citi plans to use test results to help plan its return to office strategy.
- Beginning March 12, Massachusetts is launching a new online system for booking COVID-19 vaccine appointments for the commonwealth's vaccination sites. All residents will be able to preregister for vaccinations and will be contacted when it is their turn.

### **Economic impacts and other developments**

- On March 10, the U.S. House of Representatives approved the nearly \$1.9 trillion COVID-19 stimulus plan, which will send direct payments up to \$1,400 to many Americans, expand a child tax credit and extend a \$300 weekly unemployment supplement. President Biden is expected to sign the bill into law by March 12.
- With a large percentage of Israeli citizens now vaccinated, the Jerusalem Post explains why a vaccinated individual may still become infected: Pfizer and Moderna vaccines are only 95% effective, variant strains may lower vaccine effectiveness, exposure to a high viral load from a very contagious person may overwhelm the body's immune response, and each individual's immune response is unique.
- The NHL's Pittsburgh Penguins were criticized for photoshopping face masks onto hockey fans. The manipulation of press photos was intended to give the appearance of 100% compliance with a mask requirement when, in fact, some fans were not wearing them.

Source of all data: Eaton Vance Research as of March 11, 2021 unless otherwise specified.

---

*This material is presented for informational and illustrative purposes only. This material should not be construed as investment advice, a recommendation to purchase or sell specific securities, or to adopt any particular investment strategy; it has been prepared on the basis of publicly available information, internally developed data and other third-party sources believed to be reliable. However, no assurances are provided regarding the reliability of such information and Eaton Vance has not sought to independently verify information taken from public and third-party sources.*

[Accessibility](#) | [Privacy & Security](#) | [Terms & Conditions](#) | [Form CRS](#) | [Contact](#)

Eaton Vance is part of Morgan Stanley Investment Management, the asset management division of Morgan Stanley

The information on this Web site is for U.S. residents only. The information on this Web site does not constitute an offer to sell, or a solicitation of an offer to purchase, securities in any jurisdiction to any person to whom it is not lawful to make such an offer.

There are no guarantees regarding the achievement of investment objectives, target returns, portfolio construction, allocations or measurements such as alpha, tracking error, stock weightings and other information ratios. The views and strategies described may not be suitable for all investors. Not all of Eaton Vance's recommendations have been or will be profitable. Eaton Vance does not provide tax or legal advice. Investing entails risks and there can be

no assurance that Eaton Vance (and its brands) will achieve profits or avoid incurring losses. Prospective investors should consult with a tax or legal advisor before making any investment decision.

NOT FDIC INSURED | OFFER NO BANK GUARANTEE | MAY LOSE VALUE | NOT INSURED BY ANY FEDERAL GOVERNMENT AGENCY | NOT A DEPOSIT

© Eaton Vance Management. All rights reserved. Two International Place, Boston, MA 02110